Loading stock data…
Tvardi Therapeutics (TVRD)
$1.91+0.41 (+27.33%)
Market ClosedLast close Jun 29
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tvardi Therapeutics, Inc. in the Healthcare sector is trading at $1.91 with a market capitalization of $24M. Wall Street consensus targets $8.29 (7 analysts), implying a +333.8% move over the next 12 months. The stock is currently near its 52-week low of $1.50, remaining 74.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +333.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 27) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | $2.57M |
| Operating Income | -$7.05M↑ | -$7.59M↓ | -$5.94M↑ | -$8.87M↓ | -$4.35M |
| Net Income | -$6.80M↑ | -$7.28M↓ | -$5.53M↓ | $4.17M↑ | -$9.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferativ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$24.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-106.44%
Volume
Today's trading volume
4.20M
Recent News
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Tvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Tvardi: Q3 Earnings Snapshot
SUGAR LAND, Texas (AP) — Tvardi Therapeutics, Inc. TVRD) on Thursday reported a loss of $5.5 million in its third quarter. On a per-share basis, the Sugar Land, Texas-based company said it had a loss of 59 cents.
Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now
Tvardi (TVRD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.